Plasma Exosomes Reveal the Efficacy of Targeted Therapy i... | NCT06730477

NCT06730477

Status Module

Sponsor/Collaborators Module

Name	Class
Yichang Central People's Hospital	OTHER
Suizhou Hospital, Hubei University of Medicine	UNKNOWN

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

Arms/Interventions Module

Arm Groups

Label	Description	Intervention Names
Untreated EGFR mutated lung adenocarcinoma patients	Patients diagnosed with lung adenocarcinoma with EGFR mutations for the first time.	Other: observational study
Patients with EGFR-mutated lung adenocarcinoma who are responding to targeted therapy	Patients with EGFR-mutated lung adenocarcinoma treated with targeted therapy combined with or without chemotherapy as first-line therapy, and the therapeutic effect was in the response stage.	Other: observational study
Patients with EGFR-mutated lung adenocarcinoma who are resistant to targeted therapy	Patients with EGFR-mutated lung adenocarcinoma treated with targeted therapy combined with or without chemotherapy as first-line therapy, and the therapeutic effect was in drug resistance stage, or disease progression.	Other: observational study

Interventions

Name	Type	Description	Arm Group Labels	Other Names
observational study	Other	Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.	Patients with EGFR-mutated lung adenocarcinoma who are resistant to targeted therapy

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
progression-free survival	The time of disease progression is evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1.	A two-year period after starting treatment (Regular follow-up every three months after receiving targeted therapy combined with or without chemotherapy as first-line treatment)

Secondary Outcomes

Measure	Description	Time Frame
Overall survival	The survival time after receiving targeted therapy combined with or without chemotherapy as first-line treatment	A three-year period after starting treatment (Regular follow-up every six months after receiving targeted therapy combined with or without chemotherapy as first-line treatment)

Eligibility Module

Contacts/Locations Module

Facility	Status	City	State	ZIP	Country	Contacts
Union hospital, Tongji Medical college, Huazhong University of Science and Technology		Wuhan	Hubei	430022	China

References Module

No data available